Бага насны хүүхдийн тархины хорт хавдрын эмийн хөгжилд томоохон дэвшил гарсан. Хүүхдийн тархины хавдар нь хүүхдүүдэд илүү түгээмэл тохиолддог хорт хавдар юм. Сүүлийн үеийн судалгаагаар шинэ коктейлийн эм нь бага насны хүүхдийн тархины нийтлэг хавдрыг эмчилж чаддаг болохыг тогтоожээ.
Cancer Cell” magazine recently announced that in the UK, about 400 children develop brain хавдар each year, of which the prevalence of boys is slightly higher than that of girls.
Are we able to take advantage of the results of tumor gene testing and tailor-made treatments, a strategy often referred to as personalized medicine? This treatment strategy can produce very good results for patients with brain tumors.
Neural myeloblastoma (medulloblastoma) is one of the most common хорт хавдар of the cerebellum. This тархины хавдар grows rapidly and most often occurs in children around the age of 5. Эмчилгээний сонголтууд include surgery, radiation, and chemotherapy. Although great progress has been made in treatment methods and techniques, the success rate of treating myeloblastoma still lags far behind other children’s malignancies. In particular, myeloblastoma is a highly aggressive malignancy. Only 40% of patients with medulloblastoma survive, compared with other tumors of a less severe type-with a survival rate of more than 80%.
Researchers in the United States have discovered a new combination therapy for the treatment of highly aggressive нейробластома. In laboratory tests, the drug killed хорт хавдар cells without any toxicity to normal cells, and researchers hope to conduct clinical trials of the drug. Robert Wechsler-Reya, an adjunct professor at the Sanford Burnham Prebys Medical Institute, said: “Our goal is to confirm that the drug has low toxicity properties. Because doctors and patients in this case urgently require new clinical treatment options, we will soon apply the drug from the laboratory to clinical treatment.
Бусад эмүүдтэй хавсарч хавдрыг дарангуйлдаг шинэ нэгдлүүдийг in vitro ба in vivo дэлгэцээр авдаг.
Эмнэл зүйн туршилт for neuroblastoma are often very challenging because of the limited number of patients. In addition, coupled with the variability of the disease, most treatments are only effective for one subtype of patient. Understanding which patients will respond to this treatment is one of the main goals of the trial.
"Хэрэв бид хавдрын ген дээр үндэслэн тусгайлан боловсруулсан эмчилгээг боловсруулж чадвал хувь хүний эмчилгээ гэж нэрлэдэг стратеги нь тодорхой хавдартай өвчтөнүүдэд асар их сайн мэдээг авчрах болно."
Нейробластомын ялгаатай дөрвөн төрөл байдаг бөгөөд гурав дахь бүлгийн хавдартай өвчтөнүүд хамгийн муу прогнозтой байдаг - өвчтөнүүдийн зөвхөн 40% нь удаан хугацааны туршид амьдардаг. Үүний эсрэгээр бусад нейробластомын урт хугацааны оршин тогтнох нь харьцангуй өөдрөг үзэлтэй бөгөөд өвчтөнүүдийн 80 орчим хувь нь удаан хугацаанд амьдрах чадвартай байдаг.
Нейробластома өвчтэй гурав дахь бүлгийн өвчтөнүүдийн дийлэнх нь MYC онкогены өндөр агууламжтай байдаг бөгөөд энэ нь эсийн хяналтгүй хуваагдал, хавдар үүсэх шалтгаан болдог.
There was a study on mice with a third type of neural tube cell tumors that showed histone deacetylase inhibitors (HDACIs) and phosphatidylinositol 3-kinase inhibitors (PI3KIs) might stop mice and people from making neurotubular glioblastomas without doing too much damage to normal cells.
We found several histone deacetylase inhibitors that can kill MYC oncogene-activated neural tube cell tumors without harming normal cell agents (HDACIs),” said Pei Yanxin, an assistant professor at the National Children’s Эрүүл мэндийн төв Вашингтон хотод
The most effective of these compounds is panobinostat, which has entered clinical trials in other хорт хавдрын төрөл, but has not yet been tested on neuroblastoma.” Dr. Kun-Wei, a postdoctoral researcher at Stanford University, added: “Several other studies have revealed that the mechanism of action of panobinostat is to promote the activation of the FOXO1 gene that can interfere with the oncogenes of MYC.
Phosphatidylinositol 3-kinase inhibitors (PI3KIs) are also thought to have the effect of activating the FOXO1 gene. We hypothesized that panobinostat and phosphatidylinositol 3-kinase inhibitors (PI3KIs) could work together to block хорт хавдрын эс оршин тогтнох.
“It is true that the combined treatment of these two drugs can significantly increase the survival of patients with tumors carrying the MYC gene compared to using a single drug alone.”
